These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23636137)

  • 1. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists.
    Bendtzen K
    Discov Med; 2013 Apr; 15(83):201-11. PubMed ID: 23636137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of Anti-TNF-α Biotherapies: I. Individualized Medicine Based on Immunopharmacological Evidence.
    Bendtzen K
    Front Immunol; 2015; 6():152. PubMed ID: 25904915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.
    Bendtzen K
    Immunotherapy; 2012 Nov; 4(11):1167-79. PubMed ID: 23194366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
    Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
    Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine?
    Simsek I
    Bull NYU Hosp Jt Dis; 2012; 70(3):187-90. PubMed ID: 23259626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective.
    Vincent FB; Morand EF; Murphy K; Mackay F; Mariette X; Marcelli C
    Ann Rheum Dis; 2013 Feb; 72(2):165-78. PubMed ID: 23178294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.
    Prado MS; Bendtzen K; Andrade LEC
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):985-995. PubMed ID: 28772079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring of bioavailability, pharmacokinetics and immunogenicity of tumour necrosis factor-alpha inhibitors].
    Steenholdt C; Ainsworth M; Thomsen OØ; Brynskov J; Bendtzen K
    Ugeskr Laeger; 2010 Jan; 172(1):44-7. PubMed ID: 20056095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature.
    Ingegnoli F; Favalli EG; Meroni PL
    Autoimmun Rev; 2011 Jun; 10(8):460-3. PubMed ID: 21296193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [TNF alpha-antagonists in collagen vascular disease].
    Manger K; Manger B
    Z Rheumatol; 2003 Jun; 62(3):240-5. PubMed ID: 12827400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection.
    Furst DE; Wallis R; Broder M; Beenhouwer DO
    Semin Arthritis Rheum; 2006 Dec; 36(3):159-67. PubMed ID: 16884970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of Anti-TNF-α Biotherapies: II. Clinical Relevance of Methods Used for Anti-Drug Antibody Detection.
    Bendtzen K
    Front Immunol; 2015; 6():109. PubMed ID: 25904911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms for modulating TNF alpha in immune and inflammatory disease.
    Baugh JA; Bucala R
    Curr Opin Drug Discov Devel; 2001 Sep; 4(5):635-50. PubMed ID: 12825458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.
    Matucci A; Cammelli D; Cantini F; Goletti D; Marino V; Milano GM; Scarpa R; Tocci G; Maggi E; Vultaggio A
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):3-10. PubMed ID: 27924646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.
    Spadaro A; Punzi L; Marchesoni A; Lubrano E; Mathieu A; Cantini F; Olivieri I; Salvarani C; Scarpa R; Scrivo R; Ramonda R; Porru G; D'Angelo S; Catanoso M; Atteno M; Valesini G
    Rheumatology (Oxford); 2010 Jun; 49(6):1107-11. PubMed ID: 20223813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.